I argued previously that $350 million was a too conservative number and while the increased guidance is very bullish, it still seems conservative considering the year-to-date growth trends. The low end which suggests very modest sequential net sales growth compared to the second quarter sales of $97-101 million. Based on the current prescription growth trends, I believe Amarin is on track to generate full-year net sales at least at the high end of the company’s guidance range, and possibly, significantly above it, especially if Vascepa’s label is expanded in late September.
https://seekingalpha.com/article/4273355-amarins-updated-guidance-may-still-prove-conservative
sNDA in Sept.
EVAPORATE results due in Sept.
In this study, EPA is being described as a luqiud stent.
Not only does it decrease plaque in the Artieries, it increases the size of the Lumen.
But to piggy back on those numbers again.
I think $380M-$420M is to low of an estimate too. Assuming 20% increase each Q puts us at about $435M.
Sales jumped by about 50% in the 4th Q last year when the REDUCE-IT results were announced.
https://seekingalpha.com/article/4273355-amarins-updated-guidance-may-still-prove-conservative
sNDA in Sept.
EVAPORATE results due in Sept.
In this study, EPA is being described as a luqiud stent.
Not only does it decrease plaque in the Artieries, it increases the size of the Lumen.
But to piggy back on those numbers again.
I think $380M-$420M is to low of an estimate too. Assuming 20% increase each Q puts us at about $435M.
Sales jumped by about 50% in the 4th Q last year when the REDUCE-IT results were announced.